These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 33352687)
1. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687 [TBL] [Abstract][Full Text] [Related]
2. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Moschetta M; George A; Kaye SB; Banerjee S Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296 [TBL] [Abstract][Full Text] [Related]
3. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
4. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471 [TBL] [Abstract][Full Text] [Related]
5. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
6. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071 [TBL] [Abstract][Full Text] [Related]
7. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854 [TBL] [Abstract][Full Text] [Related]
12. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis. Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study. Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869 [TBL] [Abstract][Full Text] [Related]
14. Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel. Salvati A; Carnevali I; Alexandrova E; Facchi S; Ronchi S; Libera L; Sahnane N; Memoli D; Lamberti J; Amabile S; Pepe S; Tarallo R; Sessa F; Weisz A; Tibiletti MG; Rizzo F Exp Mol Pathol; 2022 Oct; 128():104833. PubMed ID: 36165864 [TBL] [Abstract][Full Text] [Related]
15. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
16. Rucaparib: a novel PARP inhibitor for Colombo I; Lheureux S; Oza AM Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854 [TBL] [Abstract][Full Text] [Related]
17. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency? Gourley C; Miller RE; Hollis RL; Ledermann JA Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232 [TBL] [Abstract][Full Text] [Related]
18. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing. Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862 [TBL] [Abstract][Full Text] [Related]
19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
20. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]